Skip to main content

Select Drug Profiles

Immunotherapy, Oncology

Immunotherapies Steal the Show at ASCO 2015

Immunotherapy, Oncology

Combination Immunotherapy Superior to Monotherapy in Patients with Melanoma

Arming Providers and Payers with Treatment- and Value-Based Management Tools for Battling Cancer

Matthew Mitchell, PharmD, MBA, FAMCP

Lemtrada (Alemtuzumab) a New Treatment Option Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis

Farydak (Panobinostat): First HDAC Inhibitor Approved for the Treatment of Patients with Relapsed Multiple Myeloma

Lisa A. Raedler, PhD, RPh

The Continuation of Care

David B. Nash, MD, MBA

Health Economics in Oncology: A Necessary Tool for Value-Based Patient Care

Dalia Buffery, MA, ABD

Practice Management

Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer

Lorie A. Ellis, PhD, Laurence Gozalo, PhD, Marie-Hélène Lafeuille, MA, Patrick Lefebvre, MA, Scott McKenzie, MD, Dominic Pilon, MA

Stakeholder Perspective

Comparing Cost and Utilization of 2 Therapies for Metastatic Castration-Resistant Prostate Cancer

by Matthew Mitchell, PharmD, MBA, FAMCP

Practice Management

Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework

Anuja Roy, PhD, MBA, Jonathan K. Kish, PhD, MPH, Lisa M. Bloudek, PharmD, MS, David S. Siegel, MD, PhD, Sundar Jagannath, MD, Denise Globe, PhD, Emil T. Kuriakose, MD, Kristen Migliaccio-Walle, BS

Stakeholder Perspective

The Rationale for Comparing the Costs of Competing Treatment Options in Oncology

by James T. Kenney, RPh, MBA

Practice Management

Oncology Innovation and Challenging Choices: Balancing Value and Funding Priorities in Light of an Abundance of New Treatment Options

Michael Kleinrock

Page 131 of 244
Results 1301 - 1310 of 2434